Lupus eritematoso sistémico

1. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400-12.Texto completo  Resumen

2. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep;40(9):1725. Resumen

3. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271-7.Texto completo  Resumen

4. Systemic Lupus International Collaborating Clinics. SLICC classification criteria for systemic lupus erythematosus. 2012 [internet publication].Texto completo

5. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018 Apr;93(4):789-96.Texto completo  Resumen

6. Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 1;56(11):1945-61.Texto completo  Resumen

7. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018 Mar;30(2):144-50.Texto completo  Resumen

8. Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis. 2016 Jan;75(1):136-41.Texto completo  Resumen

9. Mitchet CJ Jr, McKenna CH, Elveback LR, et al. Epidemiology of systemic lupus erythematosus and other connective tissue diseases in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1985 Feb;60(2):105-13. Resumen

10. Flower C, Hennis AJ, Hambleton IR, et al. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken). 2012 Aug;64(8):1151-8.Texto completo  Resumen

11. Izmirly PM, Parton H, Wang L, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis Rheumatol. 2021 Jun;73(6):991-6. Resumen

12. Masi AT, Kaslow RA. Sex effects in SLE: a clue to pathogenesis. Arthritis Rheum. 1978 May;21(4):480-4. Resumen

13. Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum. 2007 Apr;56(4):1251-62.Texto completo  Resumen

14. Lawrence JS, Martins CL, Drake GL. A family survey of lupus erythematosus. 1. Heritability. J Rheumatol. 1987 Oct;14(5):913-21. Resumen

15. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992 Mar;35(3):311-8. Resumen

16. Kuo CF, Grainge MJ, Valdes AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015 Sep;175(9):1518-26.Texto completo  Resumen

17. Teruel M, Alarcón-Riquelme ME. The genetic basis of systemic lupus erythematosus: what are the risk factors and what have we learned. J Autoimmun. 2016 Nov;74:161-75. Resumen

18. Soni C, Reizis B. DNA as a self-antigen: nature and regulation. Curr Opin Immunol. 2018 Dec;55:31-7.Texto completo  Resumen

19. Fan Y, Li LH, Pan HF, et al. Association of ITGAM polymorphism with systemic lupus erythematosus: a meta-analysis. J Eur Acad Dermatol Venereol. 2011 Mar;25(3):271-5. Resumen

20. Wang JM, Huang AF, Yuan ZC, et al. Association of IRF5 rs2004640 polymorphism and systemic lupus erythematosus: a meta-analysis. Int J Rheum Dis. 2019 Sep;22(9):1598-606. Resumen

21. Goropevšek A, Holcar M, Avčin T. The role of STAT signaling pathways in the pathogenesis of systemic lupus erythematosus. Clin Rev Allergy Immunol. 2017 Apr;52(2):164-81. Resumen

22. Kozyrev SV, Abelson AK, Wojcik J, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008 Feb;40(2):211-6. Resumen

23. Lee YH, Bae SC. Association between the functional ITGAM rs1143679 G/A polymorphism and systemic lupus erythematosus/lupus nephritis or rheumatoid arthritis: an update meta-analysis. Rheumatol Int. 2015 May;35(5):815-23. Resumen

24. Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004 Sep;75(3):504-7.Texto completo  Resumen

25. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am. 1994 Feb;20(1):61-86. Resumen

26. Blomgren SE, Condemi JJ, Vaughan JH. Procainamide-induced lupus erythematosus: clinical and laboratory observations. Am J Med. 1972 Mar;52(3):338-48. Resumen

27. Sclienger RG, Bircher AJ, Meier CR. Minocycline-induced lupus: a systematic review. Dermatology. 2000;200(3):223-31. Resumen

28. Gordon MM, Porter D. Minocycline induced lupus: case series in the West of Scotland. J Rheumatol. 2001 May;28(5):1004-6. Resumen

29. McKellar G, Porter D, Burden D. Terbinafine as a cause of cutaneous lupus erythematosus. Rheumatology (Oxford). 2004 Feb;43(2):249. Resumen

30. Gunnarsson I, Nordmark B, Hassan Bakri A et al. Development of lupus-related side-effects in patients with early RA during sulphasalazine treatment-the role of IL-10 and HLA. Rheumatology (Oxford). 2000 Aug;39(8):886-93.Texto completo  Resumen

31. Siddiqui MA, Khan IA. Isoniazid-induced lupus erythematosus presenting with cardiac tamponade. Am J Ther. 2002 Mar-Apr;9(2):163-5. Resumen

32. Scheinfeld N. Impact of phenytoin therapy on the skin and skin disease. Expert Opin Drug Saf. 2004 Nov;3(6):655-65. Resumen

33. Pelizza L, De Luca P, La Pesa M, et al. Drug-induced systemic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed. 2006 Apr;77(1):17-9. Resumen

34. Illescas-Montes R, Corona-Castro CC, Melguizo-Rodríguez L, et al. Infectious processes and systemic lupus erythematosus. Immunology. 2019 Nov;158(3):153-60.Texto completo  Resumen

35. Li ZX, Zeng S, Wu HX, et al. The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis. Clin Exp Med. 2019 Feb;19(1):23-36.Texto completo  Resumen

36. Hanlon P, Avenell A, Aucott L, et al. Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther. 2014 Jan 6;16(1):R3.Texto completo  Resumen

37. Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015 Jun;11(6):329-41. Resumen

38. Lech M, Anders HJ. The pathogenesis of lupus nephritis. J Am Soc Nephrol. 2013 Sep;24(9):1357-66.Texto completo  Resumen

39. Frangou E, Vassilopoulos D, Boletis J, et al. An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmun Rev. 2019 Aug;18(8):751-60. Resumen

40. Boodhoo KD, Liu S, Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2016 Jul;95(29):e4272.Texto completo  Resumen

41. Haugaard JH, Kofoed K, Gislason G, et al. Association between drug use and subsequent diagnosis of lupus erythematosus. JAMA Dermatol. 2020 Nov 1;156(11):1199-207.Texto completo  Resumen

42. D'Cruz DP, Khamashta MA, Hughes GRV. Systemic lupus erythematosus. Lancet. 2007 Feb 17;369(9561):587-96. Resumen

43. Jiang F, Li S, Jia C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clin Rheumatol. 2015 Nov;34(11):1885-92. Resumen

44. Parisis D, Bernier C, Chasset F, et al. Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2019 Nov;18(11):102393. Resumen

45. Harel-Meir M. Sherer Y, Shoenfeld Y. Tobacco smoking and autoimmune disease. Nat Clin Pract Rheumatol. 2007 Dec;3(12):707-15. Resumen

46. Montes RA, Mocarzel LO, Lanzieri PG, et al. Smoking and its association with morbidity in systemic lupus erythematosus evaluated by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index: preliminary data and systematic review. Arthritis Rheumatol. 2016 Feb;68(2):441-8.Texto completo  Resumen

47. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019 Jun;78(6):736-45.Texto completo  Resumen

48. McKinley PS, Ouellette SC, Winkel GH. The contributions of disease activity, sleep patterns and depression to fatigue in SLE: a proposed model. Arthritis Rheum. 1995 Jun;38(6):826-34. Resumen

49. Leuchten N, Milke B, Winkler-Rohlfing B, et al. Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. Lupus. 2018 Aug;27(9):1431-6. Resumen

50. Zandman-Goddard G, Schoenfeld Y. SLE and infections. Clin Rev Allergy Immunol. 2003 Aug;25(1):29-40. Resumen

51. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore). 1971 Mar;50(2):85-95. Resumen

52. Vitali C, Doria A, Tincani A. International survey on the management of patients with SLE. I. General data on the participating centers and the results of a questionnaire regarding mucocutaneous involvement. Clin Exp Rheumatol. 1996 Nov-Dec;14(suppl 16):S17-22. Resumen

53. Dubois EL, Tuffanelli DL. Clinical manifestations of SLE: computer analysis of 520 cases. JAMA. 1964 Oct 12;190:104-11. Resumen

54. Kampylafka EI, Alexopoulos H, Kosmidis ML, et al. Incidence and prevalence of major central nervous system involvement in systemic lupus erythematosus: a 3-year prospective study of 370 patients. PLoS One. 2013;8(2):e55843.Texto completo  Resumen

55. Boeke A, Pullen B, Coppes L, et al. Catatonia associated with systemic lupus erythematosus (SLE): a report of two cases and a review of the literature. Psychosomatics. 2018 Nov;59(6):523-30.Texto completo  Resumen

56. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Feb;42(2):338-46.Texto completo  Resumen

57. Gu MM, Wang XP, Cheng QY, et al. A meta-analysis of cardiovascular events in systemic lupus erythematosus. Immunol Invest. 2019 Jul;48(5):505-20. Resumen

58. Li H, Tong Q, Guo L, et al. Risk of coronary artery disease in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Am J Med Sci. 2018 Nov;356(5):451-63. Resumen

59. Yazdany J, Pooley N, Langham J, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open. 2020 Sep;6(2):e001247.Texto completo  Resumen

60. Lu X, Wang Y, Zhang J, et al. Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: a systematic review and meta-analysis. Int Immunopharmacol. 2021 May;94:107466. Resumen

61. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med. 2007 Aug;28(4):441-50. Resumen

62. Duron L, Cohen-Aubart F, Diot E, et al. Shrinking lung syndrome associated with systemic lupus erythematosus: a multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. Autoimmun Rev. 2016 Oct;15(10):994-1000. Resumen

63. Beyan E, Beyan C, Turan M. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology. 2007 Jun;12(3):257-61. Resumen

64. Hallegua DS, Wallace DJ. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol. 2000 Sep;12(5):379-85. Resumen

65. Kudsi M, Nahas LD, Alsawah R, et al. The prevalence of oral mucosal lesions and related factors in systemic lupus erythematosus patients. Arthritis Res Ther. 2021 Sep 3;23(1):229.Texto completo  Resumen

66. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997 Sep;40(9):1601-11. Resumen

67. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010 Aug;69(8):1420-2. Resumen

68. American College of Rheumatology. Methodology of testing for antinuclear antibodies. 2019 [internet publication].Texto completo

69. Smeenk R, Brinkman K, van den Brink H, et al. Antibodies to DNA in patients with systemic lupus erythematosus: their role in the diagnosis, the follow-up and the pathogenesis of the disease. Clin Rheumatol. 1990 Mar;9(1 suppl 1):100-10. Resumen

70. Eaton RB, Schnneider G, Schur PH. Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum. 1983 Jan;26(1):52-62. Resumen

71. Choi MY, FitzPatrick RD, Buhler K, et al. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev. 2020 Mar;19(3):102463.Texto completo  Resumen

72. Ho RC, Thiaghu C, Ong H, et al. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun Rev. 2016 Feb;15(2):124-38. Resumen

73. Buleu F, Sirbu E, Caraba A, et al. Heart involvement in inflammatory rheumatic diseases: a systematic literature review. Medicina (Kaunas). 2019 Jun 6;55(6):249.Texto completo  Resumen

74. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with SLE: comparison with the Framingham study. Am J Epidemiol. 1997 Mar 1;145(5):408-15.Texto completo  Resumen

75. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985 Sep;64(5):285-95. Resumen

76. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep;82(5):299-308.Texto completo  Resumen

77. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002 Apr;46(4):1019-27. Resumen

78. von Mühlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum. 1995 Apr;24(5):323-58. Resumen

79. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the anti-phospholipid syndrome. Blood. 2007 Jan 15;109(2):422-30.Texto completo  Resumen

80. van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554-61. Resumen

81. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014 Jun;73(6):958-67. Resumen

82. Lehmann P, Homey B. Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev. 2009 May;8(6):456-61. Resumen

83. Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol. 2011 Jan;64(1):37-48.Texto completo  Resumen

84. Rodríguez Huerta MD, Trujillo-Martín MM, Rúa-Figueroa Í, et al. Healthy lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum. 2016 Feb;45(4):463-70. Resumen

85. Wang XR, Xiao JP, Zhang JJ, el. Decreased serum/plasma vitamin D levels in SLE patients: a meta-analysis. Curr Pharm Des. 2018;24(37):4466-73. Resumen

86. Islam MA, Khandker SS, Alam SS, et al. Vitamin D status in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Autoimmun Rev. 2019 Nov;18(11):102392. Resumen

87. Sousa JR, Cunha Rosa EP, Costa Nunes IF, et al. Effect of vitamin D supplementation on patients with systemic lupus erythematosus: a systematic review. Rev Bras Reumatol Engl Ed. Sep-Oct 2017;57(5):466-71.Texto completo  Resumen

88. de Medeiros MCS, Medeiros JCA, de Medeiros HJ, et al. Dietary intervention and health in patients with systemic lupus erythematosus: a systematic review of the evidence. Crit Rev Food Sci Nutr. 2019;59(16):2666-73. Resumen

89. Zheng R, Gonzalez A, Yue J, et al. Efficacy and safety of vitamin D supplementation in patients with systemic lupus erythematosus: a meta-analysis of randomized controlled trials. Am J Med Sci. 2019 Aug;358(2):104-14. Resumen

90. Duarte-García A, Myasoedova E, Karmacharya P, et al. Effect of omega-3 fatty acids on systemic lupus erythematosus disease activity: a systematic review and meta-analysis. Autoimmun Rev. 2020 Dec;19(12):102688. Resumen

91. Gu M, Cheng Q, Wang X, et al. The impact of SLE on health-related quality of life assessed with SF-36: a systemic review and meta-analysis. Lupus. 2019 Mar;28(3):371-82. Resumen

92. Li Z, Yang Y, Dong C, et al. The prevalence of suicidal ideation and suicide attempt in patients with rheumatic diseases: a systematic review and meta-analysis. Psychol Health Med. 2018 Oct;23(9):1025-36. Resumen

93. Fangtham M, Kasturi S, Bannuru RR, et al. Non-pharmacologic therapies for systemic lupus erythematosus. Lupus. 2019 May;28(6):703-12.Texto completo  Resumen

94. Poole JL, Bradford JD, Siegel P. Effectiveness of occupational therapy interventions for adults with systemic lupus erythematosus: a systematic review. Am J Occup Ther. 2019 Jul/Aug;73(4). Resumen

95. Chasset F, Francès C, Barete S, et al. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature. J Am Acad Dermatol. 2015 Apr;72(4):634-9. Resumen

96. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000 Jun;42(6):983-7. Resumen

97. Rodríguez SC, Olguín AM, Miralles CP, et al. Characteristics of meningitis caused by ibuprofen: report of 2 cases with recurrent episodes and review of the literature. Medicine (Baltimore). 2006 Jul;85(4):214-20. Resumen

98. Hoffman M, Gray RG. Ibuprofen-induced meningitis in mixed connective tissue disease. Clin Rheumatol. 1982 Jun;1(2):128-30. Resumen

99. Wasner CK. Ibuprofen, meningitis, and systemic lupus erythematosus. J Rheumatol. Summer 1978;5(2):162-4. Resumen

100. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010 Jan;69(1):20-8. Resumen

101. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014 Dec;132(12):1453-60.Texto completo  Resumen

102. Kim JW, Kim YY, Lee H, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol. 2017 Nov;44(11):1674-9.Texto completo  Resumen

103. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. Resumen

104. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168-78.Texto completo  Resumen

105. Wallace DJ, Ginzler EM, Merrill JT, et al. Safety and efficacy of belimumab plus standard therapy for up to thirteen years in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2019 Jul;71(7):1125-34.Texto completo  Resumen

106. Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 2018 Apr;27(5):802-11. Resumen

107. National Institute for Health and Care Excellence. Belimumab for treating active autoantibody-positive systemic lupus erythematosus. Technology appraisal guidance [TA752]. Dec 2021 [internet publication].Texto completo

108. Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Feb 25;2(2):CD010668.Texto completo  Resumen

109. Urowitz MB, Ohsfeldt RL, Wielage RC, et al. Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. Ann Rheum Dis. 2019 Mar;78(3):372-9.Texto completo  Resumen

110. Bruce IN, Mak VC, Hallett DC, et al. Factors associated with fatigue in patients with systemic lupus erythematosus. Ann Rheum Dis. 1999 Jun;58(6):379-81.Texto completo  Resumen

111. Zonana-Nacach A, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups, VI: factors associated with fatigue within five year of criteria diagnosis. Lupus. 2000;9(2):101-9. Resumen

112. Zhao Q, Deng N, Chen S, et al. Systemic lupus erythematosus is associated with negatively variable impacts on domains of sleep disturbances: a systematic review and meta-analysis. Psychol Health Med. 2018 Jul;23(6):685-97. Resumen

113. Cojocaru M, Cojocaru IM, Silosi I, et al. Manifestations of systemic lupus erythematosus. Maedica (Bucur). 2011 Oct;6(4):330-6.Texto completo  Resumen

114. William HJ, Egger MJ, Singer JZ, et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. J Rheumatol. 1994 Aug;21(8):1457-62. Resumen

115. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991 Jan 17;324(3):150-4.Texto completo  Resumen

116. Carneiro JR, Sato EI. Double-blind, randomised, placebo controlled trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999 Jun;26(6):1275-9. Resumen

117. Lupus UK. The mouth and lupus [internet publication].Texto completo

118. Altenburg A, El-Haj N, Micheli C, et al. The treatment of chronic recurrent oral aphthous ulcers. Dtsch Arztebl Int. 2014 Oct 3;111(40):665-73.Texto completo  Resumen

119. Hannon CW, McCourt C, Lima HC, et al. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;(3):CD007478.Texto completo  Resumen

120. Henderson LK, Masson P, Craig JC, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013 Jan;61(1):74-87. Resumen

121. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018 Jun 29;(6):CD002922.Texto completo  Resumen

122. Jiang YP, Zhao XX, Chen RR, et al. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Sep 18;99(38):e22328.Texto completo  Resumen

123. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797-808.Texto completo  Resumen

124. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-23.Texto completo  Resumen

125. Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus. 2006;15(6):366-70. Resumen

126. Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-28.Texto completo  Resumen

127. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):18-26. Resumen

128. Tian SY, Feldman BM, Beyene J, et al. Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis. J Rheumatol. 2014 Oct;41(10):1998-2007. Resumen

129. Zhang X, Ji L, Yang L, et al. The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis. Int Urol Nephrol. 2016 May;48(5):731-43. Resumen

130. Lee YH, Song GG. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus. 2015 Dec;24(14):1520-8. Resumen

131. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011 Feb;57(2):235-44. Resumen

132. Zhou T, Lin S, Yang S, et al. Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis. Drug Des Devel Ther. 2019 Mar 12;13:857-69.Texto completo  Resumen

133. Song GG, Lee YH. Comparison of treatment response and serious infection using tacrolimus, tacrolimus with mycophenolate mofetil, in comparison to cyclophosphamide as induction treatment for lupus nephritis. Int J Clin Pharmacol Ther. 2020 Oct;58(10):550-6. Resumen

134. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppresion in lupus nephritis: results from the MAINTAIN Nephritis trial. Ann Rheum Dis. 2010 Dec;69(12):2083-9.Texto completo  Resumen

135. Magro-Checa C, Zirkzee EJ, Huizinga TW, et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives. Drugs. 2016 Mar;76(4):459-83.Texto completo  Resumen

136. Chen Z, Zhong H, Dong G. Thrombocytopenia as a prognostic marker for systemic lupus erythematosus: a systematic review and meta-analysis. Am J Med Sci. 2019 Jun;357(6):461-7. Resumen

137. ClinicalTrials.gov. Efficacy and safety of two doses of anifrolumab compared to placebo in adult subjects with active systemic lupus erythematosus. December 2019 [internet publication].Texto completo

138. Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan 16;382(3):211-21.Texto completo  Resumen

139. Chatham WW, Furie R, Saxena A, et al. Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a phase II open-label extension study. Arthritis Rheumatol. 2021 May;73(5):816-25.Texto completo  Resumen

140. Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-80. Resumen

141. Lee YH, Bae SC. Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2018 May;77(4):335-42. Resumen

142. Emery P, Blanco R, Maldonado Cocco J, et al. Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis. RMD Open. 2017 Mar 21;3(1):e000410.Texto completo  Resumen

143. Genovese MC, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52.Texto completo  Resumen

144. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017 Jan;76(1):88-95.Texto completo  Resumen

145. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2018 Jul 21;392(10143):222-31. Resumen

146. ClinicalTrials.gov. A study of baricitinib in participants with systemic lupus erythematosus (BRAVE II). November 2021 [internet publication].Texto completo

147. ClinicalTrials.gov. A study of baricitinib in participants with systemic lupus erythematosus (SLE) (SLE-BRAVE-X). November 2021 [internet publication].Texto completo

148. ClinicalTrials.gov. A study to evaluate the safety and efficacy of obinutuzumab compared with placebo in participants with lupus nephritis (LN). November 2021 [internet publication].Texto completo

149. Furie R, Aroca G, Alvarez A, et al. Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis. Abstract number 0988: ACR Convergence 2020. Arthritis Rheumatol. 2020; 72 (suppl 10).Texto completo

150. ClinicalTrials.gov. Study of EQ001 (itolizumab) in systemic lupus erythematosus with or without active proliferative nephritis (EQUALISE). November 2021 [internet publication].Texto completo

151. Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 Jun;77(6):883-9.Texto completo  Resumen

152. Department of Health. Clinical guidelines for immunoglobulin use (2nd edition). May 2008 [internet publication].Texto completo

153. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5 year period. A multicentre prospective study of 1000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1999 May;78(3):167-75. Resumen

154. Cervera R, Abarca-Costalago M, Abramovicz D, et al. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the "Euro-Lupus Project". AAutoimmun Rev. 2006 Mar;5(3):180-6. Resumen

155. Lee YH, Choi SJ, Ji JD, et al. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016 Jun;25(7):727-34. Resumen

156. Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016 Apr;18(4):21. Resumen

157. Qian J, Wang Y, Huang C, et al. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis. Autoimmun Rev. 2016 Mar;15(3):250-7. Resumen

158. Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Nov;22(11):1435-41.Texto completo  Resumen

159. Bernatsky S, Joseph L, Boivin JF, et al. The relationship between cancer and medication exposures in systemic lupus erythematosus: a case-cohort study. Ann Rheum Dis. 2008 Jan;67(1):74-9. Resumen

160. Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional non-steroidal anti inflammatory drugs with acute renal failure: a population-based, nested case-control analysis. Am J Epidemiol. 2006 Nov 1;164(9):881-9.Texto completo  Resumen

161. Breuer GS, Baer A, Dahan D, Nesher G. Lupus-associated pancreatitis. Autoimmun Rev. 2006 May;5(5):314-8. Resumen

162. Nesher G, Breuer GS, Temprano K, et al. Lupus-associated pancreatitis. Semin Arthritis Rheum. 2006 Feb;35(4):260-7. Resumen

163. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993-7.Texto completo  Resumen

164. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus. 2004;13(9):673-8. Resumen

165. Manger K, Wildt L, Kalden JR, et al. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Autoimmun Rev. 2006 Apr;5(4):269-72. Resumen

166. Soares PM, Borba EF, Bonfa E, et al. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum. 2007 Jul;56(7):2352-61.Texto completo  Resumen

167. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996 Apr;87(4):489-93. Resumen

168. Out HJ, Bruinse HW, Christiaens GC, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol. 1992 Jul;167(1):26-32. Resumen

169. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum. 2006 Aug 15;55(4):628-35.Texto completo  Resumen

170. Wang X, Yan S, Liu C, et al. Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Osteoporos Int. 2016 Apr;27(4):1413-23. Resumen

171. Henegar CE, Eudy AM, Kharat V, et al. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review. Lupus. 2016 May;25(6):617-26. Resumen

172. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptive in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2550-8.Texto completo  Resumen

173. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15;353(24):2539-49.Texto completo  Resumen

174. Clowse ME, Magder L, Whitter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006 Nov;54(11):3640-7.Texto completo  Resumen

175. Battafarano DF, Battafarano NJ, Larsen L et al. Antigen specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998 Oct;41(10):1828-34. Resumen

176. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis. 2006 Jul;65(7):913-8.Texto completo  Resumen

177. Mathian A, Pha M, Amoura Z. Lupus and vaccinations. Curr Opin Rheumatol. 2018 Sep;30(5):465-70. Resumen

178. Huang Y, Wang H, Wan L, et al. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis. Medicine (Baltimore). 2016 May;95(19):e3637.Texto completo  Resumen

179. Pugès M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2016 Sep;55(9):1664-72.Texto completo  Resumen

180. Senecal JL, Bertrand C, Coutlee F. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy. Arthritis Rheum. 1999 Jun;42(6):1307-8.Texto completo  Resumen